AmplifyBio Patent Acquisition Opportunity

AmplifyBio is a leading contract research organization (CRO) and advanced therapy developer with capabilities spanning gene editing, mRNA, and T cell-based therapies. Founded in 2021 and backed by over $200 million in funding, AmplifyBio supported preclinical and translational programs for cutting-edge oncology and gene therapy applications. With state-of-the-art research and development facilities in Ohio and California, the company offered integrated R&D, safety testing, and GMP manufacturing services to accelerate therapeutic development for biopharma clients.

AmplifyBio’s patent portfolio comprises both internally developed technologies and patents acquired in 2022 from PACT Pharma, a clinical-stage biotechnology company specializing in TCR-based cell therapies. This acquisition contributed clinically validated IP in antigen-specific TCR identification, non-viral gene editing, and personalized cell therapies.

The portfolio encompasses 119 issued and pending patents, covering the below technologies:

These technologies are particularly relevant for companies working on:

• Adoptive Cell Therapy (ACT)
• Personalized cancer immunotherapy
• TCR-T or CAR-T platforms
• Non-viral gene editing tools
• T cell diagnostics and analytics

Interested parties should reach out to Hilco Streambank at [email protected] to obtain a nondisclosure agreement and additional information.

For Real Estate Interest:

This world-class research and development facility – owned and formerly occupied by AmplifyBio – is a purpose-built facility on 28± AC for preclinical CRO (Contract Research Organization) services. Learn more about this facility here.

AmplifyBio, LLC is a chapter 11 debtor in a bankruptcy case pending before the United States Bankruptcy Court for the Southern District of Ohio, Case No. 25-52140. Hilco Streambank’s retention by AmplifyBio and the sale process outlined herein are subject to the approval of the United States Bankruptcy Court for the Southern District of Ohio.

Hilco Streambank expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from this document or any other written or oral communication transmitted or made available to prospective purchasers. Any and all representations and warranties regarding the information described herein shall be only as negotiated and set forth in a definitive purchase agreement. Any prospective purchaser acknowledges its responsibility to perform a due diligence review prior to consummating a transaction involving the Company. Any materials or information provided, whether written or oral, do not constitute an offer or solicitation of an offer of any kind to buy or sell shares or any other securities described herein in any jurisdiction.